RNS Number : 2265F
Medica Group PLC
07 July 2023
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION

FOR IMMEDIATE RELEASE

7 July 2023

RECOMMENDED CASH ACQUISITION
OF
MEDICA group PLC ("MEDICA")
BY
moonlight BIDCO LIMITED ("bidco")
a newly incorporated wholly owned subsidiary of funds advised by
IK INVESTMENT PARTNERS LIMITED ("IK")

De-listing and Cancellation of Trading of Medica Shares

Further to the announcement made by Medica and Bidco on 6 July 2023 that the Scheme has become Effective, Medica announces that, following an application by Medica, the FCA has cancelled the listing of Medica Shares on the premium listing segment of the Official List and the London Stock Exchange has cancelled the trading of Medica Shares on the London Stock Exchange's Main Market for listed securities, in each case with effect from 7.30 a.m. (London time) today, 7 July 2023.

Defined terms used but not defined in this announcement have the meanings set out in the scheme document sent to Medica Shareholders dated 12 May 2023.

Enquiries:

Medica                                                                                                                   +44 (0)33 33 111 222
Stuart Quin, Chief Executive Officer

Richard Jones, Chief Financial Officer

 

Evercore                                                                                                                +44 (0) 20 7653 6000
(Lead Financial Adviser to Medica)

Julian Oakley

Simon Elliott

Harrison George

 

Liberum                                                                                                                 +44 (0) 20 3100 2000
(Joint Financial Adviser and Joint Broker to Medica)

Phil Walker

Mark Harrison

Richard Lindley

 

Numis                                                                                                                    +44 (0) 20 7260 1000
(Joint Financial Adviser and Joint Broker to Medica)

Freddie Barnfield

Stuart Ord

Duncan Monteith

 

FTI Consulting                                                                                                       +44 (0) 20 3727 1000
(Public Relations Adviser to Medica)                                                               medicagroupplc@fticonsulting.com

Ben Atwell

Victoria Foster Mitchell

Sam Purewal

 

Jefferies                                                                                                                 +44 (0) 20 7029 8000
(Financial Adviser to Bidco and IK)

James Thomlinson

Ashwin Pai

William Brown

 

IK

(Marketing and Communications Manager)                                                   +44 (0) 20 7304 7153

Vidya Verlkumar                                                                                                    vidya.verlkumar@ikpartners.com

 

H/Advisors Maitland                                                                                           +44 (0) 20 7379 5151
(Public Relations Adviser to Bidco and IK)                                                       IK-Maitland@h-advisors.global

Vikki Kosmalska

Finlay Donaldson

 

DLA Piper UK LLP is acting as legal adviser to Medica.

Travers Smith LLP is acting as legal adviser to Bidco and IK. 

Important Notices

Evercore Partners International LLP ("Evercore"), which is authorised and regulated by the FCA in the UK, is acting exclusively as financial adviser to Medica and no one else in connection with the matters described in this Announcement and will not be responsible to anyone other than Medica for providing the protections afforded to clients of Evercore nor for providing advice in connection with the matters referred to herein. Neither Evercore nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Evercore in connection with this Announcement, any statement contained herein, any offer or otherwise. Apart from the responsibilities and liabilities, if any, which may be imposed on Evercore by FSMA and successor legislation, or the regulatory regime established thereunder, or under the regulatory regime of any jurisdiction where exclusion of liability under the relevant regulatory regime would be illegal, void or unenforceable, neither Evercore nor any of its affiliates accepts any responsibility or liability whatsoever for the contents of this Announcement, and no representation, express or implied, is made by it, or purported to be made on its behalf, in relation to the contents of this Announcement, including its accuracy, completeness or verification of any other statement made or purported to be made by it, or on its behalf, in connection with Medica or the matters described in this Announcement. To the fullest extent permitted by applicable law, Evercore and its affiliates accordingly disclaim all and any responsibility or liability whether arising in tort, contract or otherwise (save as referred to above) which they might otherwise have in respect of this Announcement or any statement contained herein.

Liberum Capital Limited ("Liberum"), which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, is acting exclusively for Medica and no one else in connection with the Acquisition and will not be responsible to anyone other than Medica for providing the protections afforded to clients of Liberum nor for providing advice in relation to the Acquisition or any other matters referred to in this Announcement. Neither Liberum nor any of its affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Liberum in connection with this Announcement, any statement contained herein or otherwise.

Numis Securities Limited ("Numis"), which is authorised and regulated by the FCA in the United Kingdom, is acting exclusively for Medica and for no one else in connection with the Acquisition and/or any other matter referred to in this Announcement and will not be responsible to anyone other than Medica for providing the protections afforded to its clients or for providing advice in relation to the Acquisition, the contents of this Announcement, or another other matters referred to in this Announcement. Neither Numis nor any of its subsidiaries, affiliates or branches owes or accepts any duty, liability or responsibility whatsoever (whether direct, indirect, consequential, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Numis in connection with this Announcement, any statement or other matter or arrangement referred to herein or otherwise.

Jefferies International Limited ("Jefferies"), which is authorised and regulated in the United Kingdom by the FCA, is acting exclusively as financial adviser to Bidco and IK and for no one else in connection with the Acquisition and will not be responsible to anyone other than Bidco and IK for providing the protections afforded to clients of Jefferies for providing advice in relation to the Acquisition, the contents of this Announcement or any other matters referred to in this Announcement.  Neither Jefferies nor any of its affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Jefferies in connection with this Announcement, any statement contained herein or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFLLDDIRIIV